Dynavax Technologies Corp. (DVAX), which reported a 10% rise in revenue for its lead product in the first quarter, expects revenue to increase 24% to 31% for full year 2024.
The lead product is HEPLISAV-B, indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. CpG 1018 is the adjuvant used in HEPLISAV-B to provide an increased vaccine immune response.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.